New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

FDA Approves ‘Glowing Tumor’ Imaging Drug

The drug is attracted to ovarian cancer tissue and illuminates under fluorescent light to pinpoint cancer.

Only 20% of ovarian cancers are detected early, mostly because there are seldom symptoms that don’t mimic common bladder, bowel or gastrointestinal issues. However, a recent Penn Today article noted the FDA approval of Cytalux, an imaging drug for ovarian cancer that aims to improve early detection, and therefore survival rates.

Once inside the body, the drug, also known as pafolacianine, seeks out ovarian cancer tissue and illuminates it when exposed to fluorescent light. This helps surgeons precisely locate the cancer for removal and decreased chance of recurrence after initial treatment. Penn and its industry partners have also developed targeted technologies for cancer of the lung, brain, breast, sarcoma, head and neck, and urinary tract.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts